Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.35 |
| ▸ | RELA | Q04206 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20054187 | 0.86 | AKT1 (0.30) | — | |
| SCHEMBL17948012 | 0.81 | CYP11B1 (0.42) | METAP2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL23124011 | 0.79 | CYP19A1 (0.40) | — | |
| SCHEMBL4063789 | 0.78 | AKT1 (0.43) | METAP2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL4379353 | 0.78 | IDO1 (0.39) | — | |
| SCHEMBL5478060 | 0.78 | METAP2 (0.44) | METAP2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL464496 | 0.78 | MAPK1 (0.40) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL1283665 | 0.78 | KEAP1 (0.44) | METAP2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL13514507 | 0.78 | METAP2 (0.44) | METAP2 | |
| SCHEMBL1501981 | 0.78 | MAPT (0.45) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031289-A1 | POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-01-30 | — | — | US | claimed |
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3953360-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN LA ROCHE (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-112175607-B | Organic room temperature phosphorescent material and preparation method and application thereof | 华东理工大学 | 2023-01-10 | — | — | CN | disclosed |
| EP-3377483-B9 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-08-03 | — | — | EP | disclosed |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-08 | — | — | US | disclosed |
| EP-3928836-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-12-29 | — | — | EP | disclosed |
| CN-112175607-A | Organic room temperature phosphorescent material and preparation method and application thereof | 华东理工大学 | 2021-01-05 | — | — | CN | disclosed |
| CN-1768055-A | Fourth Ring imdazole derivatives as the metabotropic glutamate receptor-5 modulator | MERCK & CO INC (US) | 2006-05-03 | — | — | CN | disclosed |
| EP-1280802-B1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2004-05-06 | — | — | EP | disclosed |
| US-6620831-B2 | Cyclin dependent kinase inhibitors; anticarcinogenic and antiinflammatory agents; restenosis, angiogenesis | LG LIFE SCIENCES LTD. (KR) | 2003-09-16 | — | — | US | disclosed |
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2003-08-07 | — | — | US | disclosed |
| CN-1432015-A | Indazoles substituted with 1, 1-dioxoisothiazolidine useful as cell proliferation inhibitors | LG CHEM INVESTMENT LTD (KR) | 2003-07-23 | — | — | CN | disclosed |
| EP-1280802-A4 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2003-06-11 | — | — | EP | disclosed |
| EP-1280802-A1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG Life Sciences Ltd. (KR) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001085726-A1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2001-11-15 | — | — | WO | disclosed |
| CN-1094037-A | The N-Benzanilide derivatives | GLAXO GROUP LTD (GB) | 1994-10-26 | — | — | CN | disclosed |
| WO-1994015920-A1 | BENZANILIDE DERIVATIVES AS 5-HT1D-ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | METAP2 3781/4885RAB9A 3072/4885SMN1; SMN2 4553/4885 |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | METAP2 3781/4885RAB9A 3072/4885SMN1; SMN2 4553/4885 |
| US-20140031289-A1 | POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF | PHOSPHO1, PLCB3, INPP5D | METAP2 3599/4885RAB9A 1895/4885SMN1; SMN2 2329/4885 |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | METAP2 3781/4885RAB9A 3072/4885SMN1; SMN2 4553/4885 |
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | CCNA1, CCNI, CCNT1 | METAP2 4273/4885RAB9A 3873/4885SMN1; SMN2 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.